Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633542 | 0.83 | GAA (0.50) | — | |
| SCHEMBL13633515 | 0.74 | MAP3K5 (0.44) | — | |
| SCHEMBL13633503 | 0.71 | GAA (0.50) | — | |
| SCHEMBL1282214 | 0.71 | RXFP1 (0.41) | DHODH | |
| SCHEMBL119204 | 0.70 | PTGS1 (0.51) | — | |
| SCHEMBL23455357 | 0.69 | MKNK1 (0.57) | KMOMKNK1MKNK2PIM1PIM2 | |
| SCHEMBL30073951 | 0.69 | MKNK1 (0.57) | KMOMKNK1MKNK2PIM1PIM2 | |
| SCHEMBL4778479 | 0.69 | KMO (0.53) | KMOMKNK1MKNK2PIM1PIM2 | |
| SCHEMBL3262905 | 0.69 | ALDH1A1 (0.49) | MKNK1MKNK2CYP19A1 | |
| SCHEMBL21713059 | 0.68 | KMO (0.48) | KMOMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | PFIZER INC | 2009-11-05 | — | — | US | disclosed |
| US-7563788-B2 | Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents | PFIZER INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563788-B2 | Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents | PFIZER INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191394-A1 | Antibacterial agents | MRPL21, RPN2, FBL | KMO 4218/4885MKNK1 2780/4885MKNK2 2662/4885 |
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | DPYD, TYMP, ITPA | KMO 4206/4885MKNK1 2093/4885MKNK2 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.